May 8, 2019
Company recognized for its nanotechnology-based spinal devices
CARMEL, Indiana. (May 8, 2019) – Nanovis today announced that MedTech Outlook recognized Nanovis as a Top 10 Orthopedic Solution Provider, 2019. Its industry-leading fixation technologies offer surgeons and hospitals the best aspects of fixation, visualization, and durability. Nanovis’ developmental infection technology platforms promise to offer surgeons and hospitals much-needed bactericidal solutions.
“A distinguished panel of CMIOs, CIOs, analysts, and venture capitalists, along with the editorial panel of Med Tech Outlook has selected Nanovis as a Top 10 Orthopedic Solution Provider, We congratulate Nanovis for being at the forefront of providing cutting-edge infection technology solutions; the value these solutions offer to surgeons and hospitals is evident. We anticipate hearing more about the success of Nanovis in the years to come.”
– Alex D’souza, Managing Editor of Med Tech Outlook
“Nanovis is honored to be recognized by MedTech Outlook” says Nanovis CEO Matt Hedrick. “Recognition of our technology platforms for fixation and infection is an honor that our scientists and our surgeon collaborators are grateful to accept.”
Nanovis’ fixation technology platforms continue to perform well commercially and in testing. The FortiCore interbody system with a deeply porous titanium scaffold, intermolded with a PEEK core is attractive to surgeons who want deep porosity and the visualization and modulus benefits of PEEK. Nanovis will soon reveal favorable testing results from comparison tests of their nanotube-bioceramic surface compared to non-nanorough titanium, acid-etched nanorough titanium and calcium phosphate coated titanium.
Nanovis is a platform technology-driven growth company committed to helping surgeons and hospitals achieve excellent fixation and infection outcomes using advanced nanotechnology platforms. Its industry-leading fixation technologies offer surgeons and hospitals the best aspects of fixation, visualization, and durability. Nanovis’ developmental infection technology platforms promise to offer surgeons and hospitals much-needed bactericidal solutions
For information about distribution opportunities, please contact Jeff Shepherd, Vice President of Sales, email@example.com.
Nanovis’ mission is to develop science-enhanced, life-improving technologies. The Company’s patented and proprietary regenerative technology platforms provide differentiated surface advantages enabling the potential for existing medical devices to achieve new outcomes. Focused on aggressive, sustainable growth across multiple markets, Nanovis is commercializing science-driven platforms: the deeply porous scaffold currently available with the FortiCore® line of interbody fusion devices (deeply porous ti scaffold licensed from Sites Medical); an advanced nano-surface technology in development; a surface technology with anti-colonization and anti-microbial capabilities in pre-clinical studies, and a localized infection technology targeted toward anti-microbial resistant bacteria in pre-clinical studies